Literature DB >> 24232505

Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes?

Aleksandra Djokovic, Lj Stojanovich, N Stanisavljevic, V Bisenic, S Radovanovic, I Soldatovic, D V Simic.   

Abstract

Patients with systemic lupus erythematosus (SLE) have an increased risk of atherosclerosis. The aim of our study was to evaluate the importance of secondary antiphospholipid presence (SAPS) in light of carotid artery intima-media thickness (CIMT) changes in SLE patients. Our study included 120 patients with SLE (46.02 ± 13.16 years), 108 women and 12 men divided into two groups: 58 patients with SAPS and 62 SLE patients without SAPS taken as a control group. All patients underwent assessment of CIMT of right and left common carotid artery (CCA) and left and right internal carotid artery (ICA) by Doppler ultrasonography. In SAPS group, 48.3 % patients had significant changes of carotid arteries comparing to 16.1 % patients in control group (p = 0.008). Average CIMT values in left and right CCA and right ICA were significantly higher in SAPS group. No significant relationship between antiphospholipid antibody type and CIMT changes was established. Multivariate regression analysis revealed SAPS as a significant predictor of CIMT changes in SLE patients (p = 0.025). Presence of SAPS in SLE patients is associated with significant CIMT changes. Additional autoimmune burden leads to a need for a more aggressive education and prevention considering standard risk factors in this group of patients.

Entities:  

Mesh:

Year:  2013        PMID: 24232505     DOI: 10.1007/s00296-013-2903-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.

Authors:  Matthias W Lorenz; Joseph F Polak; Maryam Kavousi; Ellisiv B Mathiesen; Henry Völzke; Tomi-Pekka Tuomainen; Dirk Sander; Matthieu Plichart; Alberico L Catapano; Christine M Robertson; Stefan Kiechl; Tatjana Rundek; Moïse Desvarieux; Lars Lind; Caroline Schmid; Pronabesh DasMahapatra; Lu Gao; Kathrin Ziegelbauer; Michiel L Bots; Simon G Thompson
Journal:  Lancet       Date:  2012-04-27       Impact factor: 79.321

2.  Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome.

Authors:  H Der; G Kerekes; K Veres; P Szodoray; J Toth; G Lakos; G Szegedi; P Soltesz
Journal:  Lupus       Date:  2007       Impact factor: 2.911

3.  Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction.

Authors:  P Soltesz; H Der; K Veres; R Laczik; S Sipka; G Szegedi; P Szodoray
Journal:  Rheumatology (Oxford)       Date:  2008-09-09       Impact factor: 7.580

4.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 6.  Hypertension. Definitions, natural histories and consequences.

Authors:  G Pickering
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

7.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

8.  Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Sònia Jiménez; M Angels García-Criado; Dolors Tàssies; Joan Carles Reverter; Ricard Cervera; M Rosa Gilabert; Daniel Zambón; Emilio Ros; Concepció Bru; Josep Font
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580

9.  Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.

Authors:  L R Lopez; M Salazar-Paramo; C Palafox-Sanchez; B L Hurley; E Matsuura; I Garcia-De La Torre
Journal:  Lupus       Date:  2006       Impact factor: 2.911

10.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

View more
  3 in total

Review 1.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

2.  A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia.

Authors:  Nayef M Kazzaz; Allecia M Wilson; Ruba Kado; Geoffrey D Barnes; Jason S Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08       Impact factor: 4.794

Review 3.  The Sphinx's riddle: cardiovascular involvement in autoimmune rheumatic disease.

Authors:  Sophie Mavrogeni; George Markousis-Mavrogenis; Genovefa Kolovou
Journal:  BMC Cardiovasc Disord       Date:  2016-10-28       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.